A5036848123- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Enzyme Structure and Function
- Metabolism, Diabetes, and Cancer
- Colorectal Cancer Screening and Detection
- Diet, Metabolism, and Disease
- Carbohydrate Chemistry and Synthesis
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Acute Lymphoblastic Leukemia research
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Cutaneous lymphoproliferative disorders research
- Esophageal Cancer Research and Treatment
- Glycosylation and Glycoproteins Research
- Gastric Cancer Management and Outcomes
- Fluorine in Organic Chemistry
- Enzyme Catalysis and Immobilization
Nottingham City Hospital
2004-2021
Nottingham University Hospitals NHS Trust
2008-2021
University of Nottingham
1988-2016
Castle Hill Hospital
2012
Hull and East Yorkshire Hospitals NHS Trust
2012
Universitat de Barcelona
2002
Institut Català d'Oncologia
2002
Royal Marsden Hospital
1990-2000
St Bartholomew's Hospital
2000
University College Hospital
1999
PURPOSE: Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic (SLL) are malignancies that express CD20 incurable with standard therapy. A multicenter phase II study was conducted to assess the toxicity overall response rates (RR) complete (CR) rituximab (chimeric anti-CD20 monoclonal antibody). PATIENTS AND METHODS: Between January 1997 1998, 131 patients newly diagnosed MCL (MCL1; n = 34) previously treated (MCL2; 40), IMC (n 28), SLL 29) received 375 mg/m 2 /wk for...
PURPOSE: Chemotherapy for non–small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether addition of chemotherapy influences duration and quality life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) extensive (MIC2 disease. PATIENTS AND METHODS: Ambulatory patients with NSCLC, aged 75 years or younger, localized disease, were randomized MIC1 receive up four cycles (CT:...
When cure is impossible, cancer treatment should focus on both length and quality of life. Maximisation time without toxic effects could be one effective strategy to achieve these goals. The COIN trial assessed preplanned holidays in advanced colorectal this aim.
1. 2-Deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-d-mannose and 2-deoxy-2,2-difluoro-d-arabino-hexose are good substrates for yeast hexokinase. 2. 3-Deoxy-3-fluoro-d-glucose 4-deoxy-4-fluoro-d-glucose poor have very similar Km values (8×10−2m). 3. Neither α- nor β-d-glucopyranosyl fluoride is a substrate or inhibitor. 4. Studies with 2-chloro-2-deoxy- 2-O-methyl derivatives of d-glucose d-mannose revealed that little chemical modification possible at position 2 without substantial loss in...
PURPOSE: To assess the effect of a reduced dose radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, methotrexate, cytarabine (BVAM) regimen.
✓ Fifty-eight patients with histologically verified spinal cord ependymomas were treated at the Royal Marsden Hospital and Atkinson Morley's between 1950 1987. The median age in this series was 40 years (range 1 to 79 years) male:female ratio 1.8:1. Ten had tumors cervical 10 thoracic cord; 14 involved conus medullaris 24 cauda equina. Forty grade 13 grades II IV (in five there insufficient material for grading). Eleven underwent biopsy only, 33 partial or subtotal resection, complete...
Follicular lymphoma (FL) cells express CD20 and are associated in most cases with the t(14;18) chromosomal translocation. A multicentre study was undertaken between January 1997 1998 to assess complete response rate (CR) overall (RR) rituximab, a chimaeric anti-CD20 monoclonal antibody. Seventy patients previously treated FL received rituximab (375 mg/m2/week x4, by intravenous infusion). Restaging studies were performed 1 2 months after therapy. Molecular monitoring for presence of...
A review of the presenting features, management, and outcome extranodal non-Hodgkin's lymphoma (NHL) sinonasal tract during a 10-year period in Nottingham, UK.Twenty-four patients received diagnosis NHL nasal cavity, paranasal sinuses, or both, from 1987 to 1996. The patients' data were collected prospectively Nottinghamshire Lymphoma Registry.All records their histology reviewed along with entered into Registry, noting patient's age, sex, symptoms signs, staging, computed tomography...
Survival of patients with primary central nervous system lymphoma (PCNSL) has improved methotrexate-based combination regimens and radiotherapy (RT). However, the prognosis who fail or relapse after initial response is poor. Very little data available on salvage treatment at recurrence.Sixteen immunocompetent (13 males/three females, median age 54 yr) refractory (one patient) recurrent (15 patients) PCNSL, homogeneously treated diagnosis cyclophosphamide, doxorubicin, vincristine,...
PURPOSE: To assess the effect of a reduced dose radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, methotrexate, cytarabine (BVAM) regimen. PATIENTS AND METHODS: Patients received one cycle CHOD two BVAM. In first trial, all 31 45-Gy whole-brain RT (CHOD/BVAM I). second, 26 patients, was 30.6 Gy if there complete response (CR) after chemotherapy II). RESULTS: Age, performance status,...
PURPOSE To assess whether chemotherapy that includes drugs cross the blood-brain barrier improves survival in primary CNS non-Hodgkin's lymphoma (PCNSL) when combined with radiotherapy. PATIENTS AND METHODS Thirty-four patients, no evidence of human immunodeficiency virus type 1 (HIV-1) infection, were treated related regimens carmustine (BCNU), vincristine, cytarabine, and methotrexate (BVAM; 12 patients), cyclophosphamide, doxorubicin, dexamethasone (CHOD)/BVAM (17 patients) intensified...